Pharma Focus America

Gyros Protein Technologies Launches Gyrolab Generic Anti-AAV Kit to Propel Gene Therapy Innovation

Tuesday, June 18, 2024

Gyros Protein Technologies AB, known for its pioneering work in automated nanoliter-scale immunoassays and peptide synthesizers, has introduced the Gyrolab® Generic Anti-Adeno Associated Virus (AAV) Kit. This innovative kit is designed for the qualitative detection of pre-existing antibodies against AAV vectors, essential for screenings in both pre-clinical and clinical settings. It is crucial for identifying potential immune responses that could affect the success of AAV-based gene therapies.

This kit stands out as the first of its kind, capable of detecting total binding anti-capsid antibodies across the most frequently used AAV serotypes. It simplifies the screening process by removing the need for serotype-specific assays, and it reduces variability in results by eliminating the requirement for capsid labeling. This approach also requires minimal quantities of viral capsids, which helps preserve the quantity of therapeutic drugs.

Optimized for use with all Gyrolab systems, this kit extends the functionality of the Gyrolab platform into the field of bioanalysis for AAV-based gene therapies. Automation provided by Gyrolab systems minimizes variability from manual pipetting, speeds up workflows, and shortens assay development time. Results are available in just 90 minutes, accelerating the development of new gene therapies.

Mark Vossenaar, General Manager of the Biopharmaceutical Development Division at Gyros Protein Technologies, commented: “The Gyrolab Generic Anti-AAV Kit is designed to meet the specific needs of bioanalytical work in AAV-based gene therapeutics. It focuses on efficiency, resource conservation, and time-saving benefits. This new kit offers a quick, cost-effective solution for detecting total binding antibodies without the need for serotype-specific assay development or extensive optimization. It provides our customers with a convenient and reliable tool for making informed decisions based on pre-existing anti-AAV antibody screening.”

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024